Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.

Amneal vs. BioCryst: A Decade of Financial Evolution

__timestampAmneal Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 2014846150007461000
Thursday, January 1, 201510967900013047000
Friday, January 1, 201611875700011253000
Sunday, January 1, 201710904600013933000
Monday, January 1, 201823043500029514000
Tuesday, January 1, 201928959800037121000
Wednesday, January 1, 202032672700067929000
Friday, January 1, 2021365504000118818000
Saturday, January 1, 2022399700000159371000
Sunday, January 1, 2023429675000213894000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Amneal vs. BioCryst

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of key players is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A costs surged by over 400%, reflecting its aggressive expansion and operational scaling. In contrast, BioCryst's expenses grew by approximately 280%, indicating a more measured approach.

Key Insights

  • Amneal's Growth: By 2023, Amneal's SG&A expenses reached nearly five times their 2014 levels, highlighting its commitment to market penetration and innovation.
  • BioCryst's Strategy: Despite a slower growth rate, BioCryst's expenses doubled, suggesting strategic investments in niche markets.

This financial narrative underscores the diverse strategies employed by pharmaceutical companies to navigate competitive markets and drive growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025